Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
2.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
3.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 386(4): 351-363, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904799
4.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
5.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390310
6.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646664
7.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
8.
Higher Mortality in Patients With Diffuse Large B-cell Lymphoma Pre-Existing Arterial Hypertension-Real World Data of the Polish Lymphoma Research Group.
Heart Lung Circ
; 2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38616466
9.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
10.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
11.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
12.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Haematologica
; 107(6): 1335-1346, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587719
13.
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Future Oncol
; 18(36): 3961-3969, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36377973
14.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 678-689, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848462
15.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305093
16.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 378(4): 331-344, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29224502
17.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407608
18.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196165
19.
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 21(11): 1433-1442, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33035457
20.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511983